Journal ArticleDOI
Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine
Wayne K. Goodman,Lawrence H. Price,Pedro L. Delgado,Joseph Palumbo,John H. Krystal,Linda M. Nagy,Steven A. Rasmussen,George R. Heninger,Dennis S. Charney +8 more
TLDR
It is hypothesized that the mechanism of action of serotonin reuptake inhibitors in obsessive-compulsive disorder may be related to chronic treatment-induced adaptive changes in presynaptic serotonin receptor function and/or indirect influences on dopaminergic function (eg, in the basal ganglia).Abstract:
• To evaluate whether serotonin reuptake inhibition is critical to the treatment of obsessive-compulsive disorder, 40 outpatients with a principal diagnosis of obsessive-compulsive disorder were randomized in a double-blind fashion to 8 weeks of treatment with either the serotonin reuptake inhibitor fluvoxamine maleate (n = 21) or the norepinephrine reuptake inhibitor desipramine hydrochloride (n =19). Fluvoxamine was significantly better than desipramine in reducing the severity of obsessive-compulsive symptoms, as measured by the Yale-Brown Obsessive Compulsive Scale and by the global response rate ("responder" equaling "much improved"). Eleven of 21 patients were responders with fluvoxamine compared with 2 of 19 patients with desipramine. Fluvoxamine, but not desipramine, was also effective in reducing the severity of "secondary" depression. Fluvoxamine-induced improvement in symptoms of obsessive-compulsive disorder was not correlated with the severity of baseline depressive symptoms. This study provides additional evidence that the acute serotonin reuptake properties of a drug are predictive of its anti—obsessive-compulsive efficacy. It is hypothesized that the mechanism of action of serotonin reuptake inhibitors in obsessive-compulsive disorder may be related to chronic treatment-induced adaptive changes in presynaptic serotonin receptor function (eg, autoreceptor desensitization) and/ or indirect influences on dopaminergic function (eg, in the basal ganglia).read more
Citations
More filters
Journal ArticleDOI
Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder.
Lewis R. Baxter,Jeffrey M. Schwartz,Kenneth S. Bergman,Martin P. Szuba,Barry H. Guze,John C. Mazziotta,Adina Alazraki,Carl Selin,Huan-Kwang Ferng,Paul Munford,Michael E. Phelps +10 more
TL;DR: Right orbital cortex/hem was significantly correlated with ipsilateral Cd/hem and thalamus/hem before treatment but not after, and the differences before and after treatment were significant, suggesting a brain circuit involving these brain regions may mediate obsessive-compulsive disorder symptoms.
Journal ArticleDOI
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Martin A Katzman,Pierre Bleau,Pierre Blier,Pratap Chokka,Kevin Kjernisted,Michael Van Ameringen +5 more
TL;DR: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.
Book
Obsessive-Compulsive Disorder
TL;DR: New developments in the treatment of obsessive-compulsive disorder involve medications that work in conjuction with cognitive-behavioural therapy, the most promising of which is D-cycloserine.
Journal ArticleDOI
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
Christopher J. McDougle,Susan T. Naylor,Donald J. Cohen,Fred R. Volkmar,George R. Heninger,Lawrence H. Price +5 more
TL;DR: Fluvoxamine is more effective than placebo in the short-term treatment of the symptoms of autistic disorder in adults and controlled studies of fluvoxamine and other potent and selective serotonin uptake inhibitors seem warranted in children and adolescents with autism.
Journal ArticleDOI
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
TL;DR: In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.
References
More filters
Journal ArticleDOI
Development of a Rating Scale for Primary Depressive Illness
TL;DR: This is an account of further work on a rating scale for depressive states, including a detailed discussion on the general problems of comparing successive samples from a ‘population’, the meaning of factor scores, and the other results obtained.
Journal ArticleDOI
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Wayne K. Goodman,Lawrence H. Price,Steven A. Rasmussen,Carolyn M. Mazure,Roberta L. Fleischmann,Candy L. Hill,George R. Heninger,Dennis S. Charney +7 more
TL;DR: In a study involving four raters and 40 patients with obsessive-compulsive disorder at various stages of treatment, interrater reliability for the total Yale-Brown Scale score and each of the 10 individual items was excellent, with high degree of internal consistency among all item scores demonstrated with Cronbach's alpha coefficient.
Journal ArticleDOI
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Wayne K. Goodman,Lawrence H. Price,Steven A. Rasmussen,Carolyn M. Mazure,Pedro L. Delgado,George R. Heninger,Dennis S. Charney +6 more
TL;DR: Results from a previously reported placebo-controlled trial of fluvoxamine in 42 patients with obsessive-compulsive disorder showed that the Yale- Brown Scale was sensitive to drug-induced changes and that reductions in Yale-Brown Scale scores specifically reflected improvement in obsessive- compulsive disorder symptoms.
Journal ArticleDOI
Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites
Lee N. Robins,John E. Helzer,Myrna M. Weissman,Helen Orvaschel,Ernest M. Gruenberg,Jack D. Burke,Darrel A. Regier +6 more
TL;DR: Lifetime rates are presented for 15 DSM-III psychiatric diagnoses evaluated in three large household samples on the basis of lay interviewers' use of the Diagnostic Interview Schedule.
Journal ArticleDOI
Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors.
Angel Pazos,José Palacios +1 more
TL;DR: The distribution of serotonin-1 (5-HT1) receptors in the rat brain was studied by light microscopic quantitative autoradiography and the existence of 'selective' areas allowed a detailed pharmacological characterization of these sites to be made in a more precise manner than has been attained in membrane-binding studies.